Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Glenmark Life Sciences Ltd Stock Analysis

Mid Cap
Evaluated by 105 users | BSE: 543322 | NSE: GLS |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 000000031.04%463.77%134.55%72.02%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 00000000.38861,5371,8851,885
Y-o-Y Gr. Rt.-NANANANANANANA354468%73.4%22.6%-
Adjusted EPS (Rs.) 0000000-7.8918.6228.3932.8828.69
Y-o-Y Gr. Rt.-NANANANANANANANA52.5%15.8%-
Book Value per Share (Rs.) 0000000-25.428.1737.2669.83161.43
Adjusted Net Profit 0000000-0.4201306354352
Net Op. Cash Flow (Rs. Cr.) 0000000-0.510.41950-
Debt to Cash Flow from Ops 00000000000-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Glenmark Life Sciences Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales NANA1861%22.6%
Adjusted EPS NANANA15.8%
Book Value per Share 00087.4
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 000000031.04462.91124.9861.424.81
Operating Profit Margin (%) 0000000-5.2428.7130.7831.5729.56
Net Profit Margin (%) 0000000-17522.6519.9118.818.65
Debt to Equity 000000000000
Working Capital Days 00000000193248237273
Cash Conversion Cycle 00000000123160151221
Loading price chart...
Entity Percentage Holding
Promoters 82.84%
Institutions 8.49%
Non-Institutions 8.67%
Pledged *0.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Data is not available for this company.

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers.

The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities.

Business area of the company

The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Awards, accreditations and recognitions

  • 2015: Ankleshwar plant received ISO 14001:2015 certifying the management system of manufacturing  facility.
  • 2016: Dahej plant received ISO 14001:2015 certifying the management system of manufacturing facility.
  • 2016: Ankleshwar plant received BS OHSAS 18001:2017 certifying the management system of the manufacturing facility.
  • 2017: Ankleshwar plant was awarded Greentech Safety silver award by the Greentech Foundation for outstanding achievements in safety management.
  • 2018: Ankleshwar plant received ISO 14001:2015 re-certifying the management system of manufacturing facility.
  • 2018: Dahej plant received ISO 14001:2015 re-certifying the management system of manufacturing facility.
  • 2018: Ankleshwar plant was awarded Greentech Safety gold award by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Ankleshwar plant was awarded Greentech Safety Award as the winner in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Dahej plant was awarded Greentech Safety Award for the year 2019 as the runner-up in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Dahej plant was declared the winner of the Greentech Environment Award for the year 2019 for outstanding achievements in environment management in the pharmaceutical sector.
  • 2020: Dahej plant received ISO 45001:2018 certifying the management system of the manufacturing facility.
  • 2020: Dahej plant was declared the winner of the Greentech Environment Award for the year 2020 for outstanding achievements in environment protection.
  • 2021: Ankleshwar plant received ISO 45001:2018 certifying the management system of the manufacturing facility.
  • 2021: Ankleshwar plant received ISO 14001:2015 re-certifying the management system of the manufacturing facility.

Major events and milestones

  • 2001-2002: Established manufacturing plant at Kurkumbh, Maharashtra.
  • 2001-2002: The company’s Promoter established its API business.
  • 2004: Commenced manufacturing at Mohol, Maharashtra.
  • 2008: Ankleshwar plant at Gujarat inspected by US-FDA.
  • 2012: Ankleshwar plant inspected by PMDA and AFSSAPS.
  • 2013: Commenced manufacturing at Dahej, Gujarat.
  • 2013: Ankleshwar plant inspected by COFEPRIS.
  • 2015: Dahej plant inspected by US-FDA.
  • 2016: Dahej plant inspected by PMDA Japan.
  • 2018: Dahej plant inspected by EDQM, ANSM and US-FDA.
  • 2018: Mohol plant inspected by US-FDA.
  • 2019: The API business was spun off into Company.
  • 2019: Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan.
  • 2021: Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback